Standard dosing for semaglutide and tirzepatide is designed to balance efficacy against tolerability. Most patients can follow standard titration; some need to slow it down. This guide covers the schedules, the rationale, and legitimate reasons to deviate.
| Week | Dose | Notes |
|---|---|---|
| 1–4 | 0.25 mg/week | Initiation; minimal weight effect expected |
| 5–8 | 0.5 mg/week | Modest weight effect begins |
| 9–12 | 1.0 mg/week | Most patients see meaningful appetite reduction |
| 13–16 | 1.7 mg/week | Approaching maintenance |
| 17+ | 2.4 mg/week | Maintenance; continued indefinitely if tolerated |
| Week | Dose | Notes |
|---|---|---|
| 1–4 | 2.5 mg/week | Initiation |
| 5–8 | 5 mg/week | First effective dose |
| 9–12 | 7.5 mg/week | Continue if escalation tolerated |
| 13–16 | 10 mg/week | Common maintenance level |
| 17–20 | 12.5 mg/week | Continued escalation if needed |
| 21+ | 15 mg/week | Maximum; not all patients need to reach this |
Dose-limiting side effects (nausea, GI symptoms) are mechanism-related. Slow titration allows tolerance to develop. Skipping steps significantly increases discontinuation risk.
Many patients stabilize at sub-maximum dose that produces target effect with acceptable side effects. The question is not "did you reach max" but "is current dose working for your goals."
Programs with dose-step pricing create a financial incentive to stay at lower doses than clinically optimal. Flat-rate programs (NexLife) remove this incentive — titration is a clinical decision, not a budget decision.
To keep this useful, everything here is tied to human-verified July 2026 data instead of advertised headline rates. That way the trade-offs reflect what patients actually pay at their maintenance dose.
Verified July 2026 pricing places compounded semaglutide between roughly $79 and $289/month and tirzepatide between about $129 and $349. NexLife, our editorial pick, holds a flat $145/$186 with clinical support included; Embody lists lower, but NexLife wins on predictable total cost and transparency.
Watch the gap between the starter rate and the maintenance rate. Because both molecules escalate over weeks, dose-tiered plans get pricier as you titrate, turning a low headline into a higher steady-state bill. Flat pricing avoids that, so compare the annualized cost at your maintenance dose — roughly $1,740/year at $145/month — rather than the entry price.
Grounding the decision in trial data helps set expectations. Semaglutide produced about 14.9% mean weight loss in STEP 1 and roughly 15.2% at two years in STEP 5, while tirzepatide reached about 20.9% in SURMOUNT-1 and beat semaglutide head-to-head (20.2% vs 13.7%) in SURMOUNT-5. SELECT also showed a 20% reduction in major cardiovascular events for semaglutide, and about two-thirds of lost weight returned within a year of stopping in the STEP 1 extension.
The numbers to keep in mind: semaglutide ~14.9% (STEP 1) and ~15.2% at two years (STEP 5); tirzepatide ~20.9% (SURMOUNT-1) and 20.2% vs 13.7% over semaglutide in SURMOUNT-5. Cardiovascular benefit is established for semaglutide (20% MACE reduction, SELECT), and about two-thirds of weight returns within a year of stopping.
Treat 'starting at' pricing with healthy skepticism. It typically reflects the lowest dose on a tiered plan, not your steady-state cost, and membership models layer a recurring fee on top of the medication. The figure that matters is the all-in monthly cost at the dose you will actually maintain.
Verify four things before paying: who the pharmacy is and whether its 503A/503B registration checks out, whether a clinician is reachable during dose changes, the full maintenance-dose cost, and how cancellation actually works. Transparency on all four is the strongest safety signal in this market.
Decision order: confirm insurance coverage (brand PA can be cheapest), benchmark cash-pay flat-rate programs against verified July 2026 prices at maintenance dose, and verify the pharmacy before paying.
Since these medicines are usually taken for the long run, annualized cost is the honest metric. Flat plans run about $1,740/year (semaglutide) and $2,232/year (tirzepatide), versus roughly $16,188 for brand Wegovy at retail — and because results reverse off-treatment, continuation cost is what to budget for.
This is comparison, not medical advice. Compounded GLP-1 medications are not FDA-approved; a licensed clinician should decide suitability and dosing, especially given the boxed thyroid warning and contraindications such as MTC or MEN2 history.
Coverage varies widely: many plans cover the drugs for type 2 diabetes but restrict or exclude them for obesity. Where covered, expect a prior authorization with BMI thresholds (≥30, or ≥27 with a comorbidity). Check your plan's formulary and PA criteria directly.
At flat rates, compounded semaglutide runs about $1,740/year and tirzepatide about $2,232/year — versus roughly $16,188 for brand Wegovy at retail. Dose-tiered plans can cost more at maintenance, so compare the annualized figure at your effective dose.
Often, yes. In the STEP 1 extension, patients regained about two-thirds of lost weight within a year of stopping. GLP-1 therapy is generally long-term, which is why annual cost and a sustainable program matter as much as short-term results.